These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 19142167

  • 1. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery.
    Kane S, Ford J, Cohen R, Wagner C.
    J Clin Gastroenterol; 2009 Aug; 43(7):613-6. PubMed ID: 19142167
    [Abstract] [Full Text] [Related]

  • 2. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn.
    Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC.
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1255-8. PubMed ID: 17045211
    [Abstract] [Full Text] [Related]

  • 3. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA, Villela R, Silverberg MS, Greenberg GR.
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [Abstract] [Full Text] [Related]

  • 4. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q, Hogezand RA, Lamers CB, Verspaget HW.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):585-92. PubMed ID: 15339330
    [Abstract] [Full Text] [Related]

  • 5. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease.
    Ben-Horin S, Yavzori M, Kopylov U, Picard O, Fudim E, Eliakim R, Chowers Y, Lang A.
    J Crohns Colitis; 2011 Dec 01; 5(6):555-8. PubMed ID: 22115374
    [Abstract] [Full Text] [Related]

  • 6. The role of breast milk in protecting urban Peruvian children against cryptosporidiosis.
    Sterling CR, Gilman RH, Sinclair NA, Cama V, Castillo R, Diaz F.
    J Protozool; 1991 Dec 01; 38(6):23S-25S. PubMed ID: 1818182
    [Abstract] [Full Text] [Related]

  • 7. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
    Atzeni F, Ardizzone S, Sarzi-Puttini P, Colombo E, Maconi G, De Portu S, Carrabba M, Bianchi Porro G.
    Aliment Pharmacol Ther; 2005 Sep 01; 22(5):453-61. PubMed ID: 16128684
    [Abstract] [Full Text] [Related]

  • 8. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
    Miheller P, Muzes G, Zágoni T, Tóth M, Rácz K, Tulassay Z.
    Orv Hetil; 2005 Jul 10; 146(28):1477-80. PubMed ID: 16130441
    [Abstract] [Full Text] [Related]

  • 9. Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients.
    Di Sabatino A, Ciccocioppo R, Benazzato L, Sturniolo GC, Corazza GR.
    Aliment Pharmacol Ther; 2004 May 01; 19(9):1019-24. PubMed ID: 15113369
    [Abstract] [Full Text] [Related]

  • 10. Effect of preterm birth and antenatal corticosteroid treatment on lactogenesis II in women.
    Henderson JJ, Hartmann PE, Newnham JP, Simmer K.
    Pediatrics; 2008 Jan 01; 121(1):e92-100. PubMed ID: 18166549
    [Abstract] [Full Text] [Related]

  • 11. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
    Gaertner WB, Decanini A, Mellgren A, Lowry AC, Goldberg SM, Madoff RD, Spencer MP.
    Dis Colon Rectum; 2007 Nov 01; 50(11):1754-60. PubMed ID: 17899271
    [Abstract] [Full Text] [Related]

  • 12. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.
    Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR.
    Am J Gastroenterol; 2004 Dec 01; 99(12):2385-92. PubMed ID: 15571587
    [Abstract] [Full Text] [Related]

  • 13. Infliximab therapy in Crohn's disease: a pragmatic approach?
    Kevans D, Keegan D, Mulcahy HE, O'Donoghue DP.
    Aliment Pharmacol Ther; 2006 Jul 15; 24(2):351-9. PubMed ID: 16842462
    [Abstract] [Full Text] [Related]

  • 14. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study.
    Ryan BM, Russel MG, Schurgers L, Wichers M, Sijbrandij J, Stockbrugger RW, Schoon E.
    Aliment Pharmacol Ther; 2004 Oct 15; 20(8):851-7. PubMed ID: 15479356
    [Abstract] [Full Text] [Related]

  • 15. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
    Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U.
    Gastroenterology; 2018 Sep 15; 155(3):696-704. PubMed ID: 29857090
    [Abstract] [Full Text] [Related]

  • 16. Maternal antibodies in breast milk protect the child from enterovirus infections.
    Sadeharju K, Knip M, Virtanen SM, Savilahti E, Tauriainen S, Koskela P, Akerblom HK, Hyöty H, Finnish TRIGR Study Group.
    Pediatrics; 2007 May 15; 119(5):941-6. PubMed ID: 17473095
    [Abstract] [Full Text] [Related]

  • 17. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab.
    Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin JM, Watier H, Goupille P, Paintaud G.
    Ther Drug Monit; 2006 Apr 15; 28(2):169-74. PubMed ID: 16628126
    [Abstract] [Full Text] [Related]

  • 18. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
    Zelinkova Z, van der Ent C, Bruin KF, van Baalen O, Vermeulen HG, Smalbraak HJ, Ouwendijk RJ, Hoek AC, van der Werf SD, Kuipers EJ, van der Woude CJ, Dutch Delta IBD Group.
    Clin Gastroenterol Hepatol; 2013 Mar 15; 11(3):318-21. PubMed ID: 23103819
    [Abstract] [Full Text] [Related]

  • 19. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease.
    Eivindson M, Grønbaek H, Skogstrand K, Thorsen P, Frystyk J, Flyvbjerg A, Dahlerup JF.
    Scand J Gastroenterol; 2007 Apr 15; 42(4):464-70. PubMed ID: 17454856
    [Abstract] [Full Text] [Related]

  • 20. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.
    Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P.
    Gastroenterology; 2009 Nov 15; 137(5):1628-40. PubMed ID: 19664627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.